After Roche (RHHBY) reported negative Phase 3 topline data for gantenerumab in Alzheimer’s disease, Jefferies analyst Michael Yee said he believes the scarcity value of Prothena’s (PRTA) PRX-012 has gone up. While Roche’s miss was “generally consistent” with his expectation, he continues to view PRX-012 as “differentiated” as a wholly-owned, “very potent,” subQ antibody, which he thinks “large pharma could have increased interest in going forward.” Yee reiterates a Buy rating and $100 price target on Prothena shares, which are down $4.01, or 7%, to $52.88 in Monday pre-market trading following Roche’s news.